{"id":"https://openalex.org/W2183844286","doi":null,"title":"Comparative Study of Lipid and Glycemic Effects of Pioglitazone, Rosiglitazone with Glibenclamide in Patients with Type 2 Diabetes and Dyslipidemia","display_name":"Comparative Study of Lipid and Glycemic Effects of Pioglitazone, Rosiglitazone with Glibenclamide in Patients with Type 2 Diabetes and Dyslipidemia","publication_year":2014,"publication_date":"2014-01-01","ids":{"openalex":"https://openalex.org/W2183844286","mag":"2183844286"},"language":"en","primary_location":{"id":"mag:2183844286","doi":null,"is_oa":false,"landing_page_url":"http://www.idosi.org/gjp/8(1)14/17.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5092376368","display_name":"Inbaraj Susai Domnic","orcid":"https://orcid.org/0000-0003-4018-2753","observed_orcids":["https://orcid.org/0000-0003-4018-2753"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. D. Inbaraj","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5000625527","display_name":"I. Glory Josephine","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"I. Glory Josephine","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.4358,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.64008528,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":94},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9702000021934509,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9702000021934509,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.014600000344216824,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.007699999958276749,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pioglitazone","display_name":"pioglitazone","score":0.9679999947547913},{"id":"https://openalex.org/keywords/rosiglitazone","display_name":"rosiglitazone","score":1.0},{"id":"https://openalex.org/keywords/glibenclamide","display_name":"glibenclamide","score":0.9710000157356262},{"id":"https://openalex.org/keywords/thiazolidinediones","display_name":"thiazolidinediones","score":0.9610000252723694},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9409999847412109},{"id":"https://openalex.org/keywords/dyslipidemia","display_name":"dyslipidemia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.7950000166893005},{"id":"https://openalex.org/keywords/lipid-profile","display_name":"lipid profile","score":0.7900000214576721},{"id":"https://openalex.org/keywords/hdl-cholesterol","display_name":"HDL cholesterol","score":0.9649999737739563},{"id":"https://openalex.org/keywords/triglycerides","display_name":"triglycerides","score":0.9350000023841858},{"id":"https://openalex.org/keywords/total-cholesterol","display_name":"total cholesterol","score":0.9399999976158142},{"id":"https://openalex.org/keywords/liver-enzymes","display_name":"liver enzymes","score":0.652999997138977},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.921999990940094},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":0.8090000152587891},{"id":"https://openalex.org/keywords/cardiovascular-risk-prevention","display_name":"cardiovascular risk prevention","score":0.6809999942779541}],"concepts":[{"id":"https://openalex.org/C2778384471","wikidata":"https://www.wikidata.org/wiki/Q417765","display_name":"Pioglitazone","level":4,"score":0.9635291695594788},{"id":"https://openalex.org/C2780152017","wikidata":"https://www.wikidata.org/wiki/Q424771","display_name":"Rosiglitazone","level":3,"score":0.9291234016418457},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8361979722976685},{"id":"https://openalex.org/C2778096610","wikidata":"https://www.wikidata.org/wiki/Q1476525","display_name":"Dyslipidemia","level":3,"score":0.7509676218032837},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.73583984375},{"id":"https://openalex.org/C2776923340","wikidata":"https://www.wikidata.org/wiki/Q1393556","display_name":"Thiazolidinedione","level":4,"score":0.6324506402015686},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.6225350499153137},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6169770359992981},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.594173014163971},{"id":"https://openalex.org/C2779768347","wikidata":"https://www.wikidata.org/wiki/Q420626","display_name":"Glibenclamide","level":3,"score":0.5635114312171936},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5331541299819946},{"id":"https://openalex.org/C2778270857","wikidata":"https://www.wikidata.org/wiki/Q2723972","display_name":"Lipid profile","level":3,"score":0.4513470530509949},{"id":"https://openalex.org/C2777482532","wikidata":"https://www.wikidata.org/wiki/Q668093","display_name":"Atorvastatin","level":2,"score":0.4250236451625824}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2183844286","doi":null,"is_oa":false,"landing_page_url":"http://www.idosi.org/gjp/8(1)14/17.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7100501794","https://openalex.org/W2049571309","https://openalex.org/W2129563195","https://openalex.org/W7218130992","https://openalex.org/W37315064","https://openalex.org/W1963886325","https://openalex.org/W2994312674","https://openalex.org/W2120086542","https://openalex.org/W2107298817","https://openalex.org/W2109934064"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"evaluate":[2],"the":[3,35,55,181,242,265,276],"lipid":[4],"and":[5,25,50,63,101,111,117,129,157,209,280,282],"glycemic":[6],"effects":[7,235,249],"of":[8,11,40,43,74,97,138,180,224,250,257,268],"Thiazolidinedione":[9],"group":[10,72,120,171,176,195,200,223,256],"drugs":[12,227,258],"(Pioglitazone,":[13],"Rosiglitazone)":[14],"in":[15,127,147,152,155,159,169,193,201,207,215,264],"Type":[16,28,269],"2":[17,29,238,270],"diabetic":[18,30,36,239],"patients":[19,31,52,76],"with":[20,32,143],"dyslipidemia.Methodogy:":[21],"After":[22],"ethical":[23],"clearance":[24],"informed":[26],"consent":[27],"dyslipidemia":[33,281],"attending":[34],"out":[37],"patient":[38],"clinic":[39],"Diabetology":[41],"unit":[42],"Voluntary":[44],"health":[45],"services":[46],"hospital.Chennai":[47],"were":[48,107],"screened":[49],"45":[51],"selected":[53],"for":[54,61,69,262],"study":[56,139],"according":[57],"to":[58,174,198,273,284],"WHO":[59],"criteria":[60],"diabetes":[62,271],"National":[64],"cholesterol":[65,149,184],"Education":[66],"program":[67],"guidelines":[68],"dyslipidemia.":[70],"Each":[71],"consisting":[73],"15":[75,88],"viz.,":[77],"Group":[78,84,90],"I:":[79],"Received":[80,86,92],"Glibenclamide":[81],"5":[82],"mg/day.":[83,89,95],"II:":[85],"Pioglitazone":[87,119],"III:":[91],"Rosiglitazone":[93,170],"4":[94],"Estimation":[96],"serum":[98],"Total":[99],"Cholesterol":[100],"HDL":[102,183,252],"Cholesterol,Triglycerides,VLDL,":[103],"Blood":[104],"glucose,SGOT,S.GPT":[105],"levels":[106,211],"estimated.":[108],"Anthropometric":[109],"evaluation":[110],"clinical":[112],"parameters":[113],"also":[114],"evaluated.":[115],"Results":[116],"discussion:":[118],"showed":[121,164,187,204,246],"significant":[122,165,188,205],"reduction":[123,166],"(p":[124,190,212],"<":[125,191,213],"0.05)":[126],"fasting":[128],"post":[130],"prandial":[131],"blood":[132],"glucose":[133],"level":[134,185],"at":[135,177],"12":[136,178],"week":[137,179],"th":[140,186,203],"when":[141,172,196],"compared":[142,173,197],"sulphonylurea":[144,160,175,199],"group.":[145,161,221],"Reduction":[146],"total":[148],"level.":[150],"16%":[151],"pioglitazone,":[153],"4%":[154],"rosiglitazone":[156,220],"1%":[158],"Serum":[162],"Triglycerides":[163],"(P<":[167],"0.001)":[168,192,214],"study.":[182],"increase":[189,206],"pioglitazone":[194,216,245],"8":[202],"SGOT":[208],"SGPT":[210],"as":[217,219,230,232],"well":[218,231],"Conclusion:Thiazolidinediones":[222],"oral":[225],"antidiabetic":[226],"shows":[228],"hypoglycemic":[229],"favourable":[233,248],"lipidemic":[234],"on":[236],"type":[237],"patients.":[240],"Among":[241],"two":[243],"glitazones,":[244],"more":[247],"increasing":[251],"cholesterol.":[253],"Hence":[254],"this":[255],"may":[259],"be":[260],"considered":[261],"use":[263],"early":[266],"stage":[267],"judiciously":[272],"tide":[274],"over":[275],"insulin":[277],"resistance,":[278],"hyperglycemia":[279],"thereby":[283],"prevent":[285],"cardiovascular":[286],"morbidity.":[287]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2016-06-24T00:00:00"}